Tag Archives: clinicaltrials.gov

Currently recruiting trial update

Posted on by

In response to a reader’s question, here’s the most current list I can create of current or imminent clinical pharmacological neuroprotective treatment trials in PSP.  Maybe soon I’ll list the trials not covered by that list of adjectives, but you can do that yourself at www.clinicaltrials.gov.

For more information, including a phone number or email address, go to www.clinicaltrials.gov and search on the National Clinical Trials number shown or on the disease and drug names.  For the trial in Australia/New Zealand, use the link given.

  • Relyvrio (AMX-0035): A orally-administered combination of two existing medications to help brain cells resist the PSP process.  Will recruit 600 patients in the US, Canada, Europe and Japan. NCT06122662
  • NIO-752: An antisense oligonucleotide given by spinal injection once a month.  Still recruiting only in Germany and the UK.  A small, 3-month trial primarily designed to assess safety and tolerability. NCT04539041
  • GV-1001: a subcutaneously protein fragment administered daily by subcutaneous injection. A small trial primarily designed to assess safety and tolerability.  South Korea only.  NCT05819658

  • Set to start in a few months is the study of FNP-223.  This year-long trial will take place at dozens of sites in the US, Europe and Japan.  It’s an oral pill taken 3 times a day that reduces the abnormal phosphorylation and misfolding of tau.  It’s not yet on www.clinicaltrials.gov. 

You may be interested in joining an observational trial, where there’s no treatment – only testing and examinations, typically with the goal of developing new diagnostic tests and gathering other information of potential future use in developing new treatments.  If so, visit www.clinicaltrials.gov and search on PSP and, in the “focus” column, on “observational studies.”  One that I’d recommend highly is the ALLFTD study.  It’s centered around frontotemporal dementia but also includes PSP.  I know the people running it, and it’s a first-rate study that has already recruited several hundred people with PSP.  NCT04363684

Disclosures: I am, or have been, a paid consultant for the companies that make Relyvrio, NIO-752 and FNP-223. But I have no stock in the companies or other financial interest in the success of these drugs.